Effect of Rosiglitazone on Inflammation in Peritoneal Dialysis Patients
- VernacularTitle:罗格列酮对腹膜透析患者微炎症反应状态的影响
- Author:
Bingxin LI
;
Xiaobing ZHOU
;
Lin YANG
;
Jingbiao XIA
;
Wenqi ZHONG
- Publication Type:Journal Article
- Keywords:
Rosiglitazone;
Peritoneal dialysis;
Inflammation;
Insulin resistance
- From:
China Pharmacist
2014;(5):827-829
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the effect of rosiglitazone on inflammation in peritoneal dialysis patients. Methods:Fifty patients undergoing continuous ambulatory peritoneal dialysis were collected in our hospital. The treatment group was assigned to receive regular peritoneal dialysis and rosiglitazone 4mg once daily while the control group was received regular peritoneal dialysis for 12 weeks. Such serum examinations as fasting blood glucose (FBG), glycosylated hemoglobin A1c, haemoglobin, serum total cholesterol, high density lipoprotein cholesterol(HDL-C), low density lipoprotein cholesterol, triglycerides and high sensitivity C reactive protein (hs-CRP) were measured, tumor necrosis factorα(TNF-α) and interleukin-6 (IL-6) levels were measured by ELISA, and homeostasis model as-sessment of insulin resistance( HOMA-IR) was also evaluated before and after the treatment. Results:After the 12-week treatment by rosiglitazone, the levels of FPG, HOMA-IR, hs-CRP, TNF-αand IL-6 were declined significantly(P<0. 05), and the level of HDL-C was increased significantly(P<0. 05). Conclusion: Rosiglitazone shows significant anti-inflammatory, insulin resistance improve-ment and anti-lipidemic effects in peritoneal dialysis patients.
